English
French
Monte bar
 |
Neurodegenerative Brain Diseases (Montelukast) |
|
|
|
Monte
INDICATED FOR DEGENERATIVE DISEASES OF THE BRAIN
Montelukast VersaFilm® is a unique drug opportunity for the treatment of neurodegenerative diseases of the brain, such as mild cognitive impairment, Alzheimer’s disease and dementia.
IntelGenx is working to re-formulate the drug using VersaFilm®, IntelGenx’s proprietary thin film technology, to repurpose Montelukast as a therapeutic to treat neurodegenerative diseases.
Currently, Montelukast is marketed as Singulair® (Merck & Co.), a once daily tablet for the chronic treatment of asthma and seasonal allergic rhinitis. The drug was first approved by the U.S. Food and Drug Administration in 1997 and has a very good safety profile. Montelukast is a leukotriene receptor antagonist that reduces leukotriene-induced bronchoconstriction, decreasing inflammation.
It is believed that leukotriene signalling also plays a role in brain inflammation, and that montelukast could have a positive impact on inflammatory processes in the brain, improving memory impairment.
middle icons
chronic treatment of asthma and seasonal allergic rhinitis
very good safety profile
relieve symptoms of seasonal allergies
reduce the bronchoconstriction
monte vs
|
|||
|
|
||
Excellent safety profile
Improved bioavailability
Crosses the blood-brain-barrier
middle text
In a recent Phase I study, IntelGenx demonstrated that an oral film formulation of Montelukast is safe and well-tolerated in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film. IntelGenx's Montelukast VersaFilm® also crosses the blood-brain barrier, an essential feature for treating degenerative brain diseases.
IntelGenx is currently preparing for a Phase 2a proof of concept study to assess the safety, feasibility, tolerability, and efficacy of Montelukast VersaFilm® in patients with mild to moderate Alzheimer's Disease.
IntelGenx plans to establish a strategic partnership for the development and subsequent commercialization of a branded differentiated montelukast film product, Montelukast VersaFilm®
More Info
monte Button
bottom text
PARTNER WITH US >>
IntelGenx plans to establish a strategic partnership for the development and subsequent commercialization of a branded differentiated loxapine film product, montelukast VersaFilm®.
Product Warning
PRODUCT WARNING
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
PRESCRIBING INFORMATION
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.